These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ecotropic viral integration site 1, a novel oncogene in prostate cancer. Queisser A; Hagedorn S; Wang H; Schaefer T; Konantz M; Alavi S; Deng M; Vogel W; von Mässenhausen A; Kristiansen G; Duensing S; Kirfel J; Lengerke C; Perner S Oncogene; 2017 Mar; 36(11):1573-1584. PubMed ID: 27617580 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer. Jazaeri AA; Ferriss JS; Bryant JL; Dalton MS; Dutta A Gynecol Oncol; 2010 Aug; 118(2):189-95. PubMed ID: 20462630 [TBL] [Abstract][Full Text] [Related]
5. Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity. Sayadi A; Jeyakani J; Seet SH; Wei CL; Bourque G; Bard FA; Jenkins NA; Copeland NG; Bard-Chapeau EA Oncogene; 2016 May; 35(18):2311-21. PubMed ID: 26234679 [TBL] [Abstract][Full Text] [Related]
6. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia. Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728 [TBL] [Abstract][Full Text] [Related]
7. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Nanjundan M; Nakayama Y; Cheng KW; Lahad J; Liu J; Lu K; Kuo WL; Smith-McCune K; Fishman D; Gray JW; Mills GB Cancer Res; 2007 Apr; 67(7):3074-84. PubMed ID: 17409414 [TBL] [Abstract][Full Text] [Related]
8. EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor-β-mediated growth inhibition in hepatocellular carcinoma. Yasui K; Konishi C; Gen Y; Endo M; Dohi O; Tomie A; Kitaichi T; Yamada N; Iwai N; Nishikawa T; Yamaguchi K; Moriguchi M; Sumida Y; Mitsuyoshi H; Tanaka S; Arii S; Itoh Y Cancer Sci; 2015 Jul; 106(7):929-37. PubMed ID: 25959919 [TBL] [Abstract][Full Text] [Related]
9. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells. Maicas M; Vázquez I; Alis R; Marcotegui N; Urquiza L; Cortés-Lavaud X; Cristóbal I; García-Sánchez MA; Odero MD Biochim Biophys Acta Gene Regul Mech; 2017 Jun; 1860(6):721-729. PubMed ID: 28391050 [TBL] [Abstract][Full Text] [Related]
10. EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells. Rommer A; Steinmetz B; Herbst F; Hackl H; Heffeter P; Heilos D; Filipits M; Steinleitner K; Hemmati S; Herbacek I; Schwarzinger I; Hartl K; Rondou P; Glimm H; Karakaya K; Krämer A; Berger W; Wieser R PLoS One; 2013; 8(2):e56308. PubMed ID: 23457546 [TBL] [Abstract][Full Text] [Related]
11. Expression and activation of P38 MAP kinase in invasive ductal breast cancers: correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins. Merlin JL; Harlé A; Lion M; Ramacci C; Leroux A Oncol Rep; 2013 Oct; 30(4):1943-8. PubMed ID: 23900300 [TBL] [Abstract][Full Text] [Related]
12. EVI‑1 acts as an oncogene and positively regulates calreticulin in breast cancer. Wu L; Wang T; He D; Li X; Jiang Y Mol Med Rep; 2019 Mar; 19(3):1645-1653. PubMed ID: 30592274 [TBL] [Abstract][Full Text] [Related]
13. HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1. Yang Y; Leonard M; Zhang Y; Zhao D; Mahmoud C; Khan S; Wang J; Lower EE; Zhang X Cancer Res; 2018 Jan; 78(2):422-435. PubMed ID: 29187405 [TBL] [Abstract][Full Text] [Related]
14. The role of EVI1 in myeloid malignancies. Glass C; Wilson M; Gonzalez R; Zhang Y; Perkins AS Blood Cells Mol Dis; 2014; 53(1-2):67-76. PubMed ID: 24495476 [TBL] [Abstract][Full Text] [Related]
15. Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes. Konrad TA; Karger A; Hackl H; Schwarzinger I; Herbacek I; Wieser R J Leukoc Biol; 2009 Oct; 86(4):813-22. PubMed ID: 19605700 [TBL] [Abstract][Full Text] [Related]
17. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Wieser R Gene; 2007 Jul; 396(2):346-57. PubMed ID: 17507183 [TBL] [Abstract][Full Text] [Related]
18. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Fenouille N; Bassil CF; Ben-Sahra I; Benajiba L; Alexe G; Ramos A; Pikman Y; Conway AS; Burgess MR; Li Q; Luciano F; Auberger P; Galinsky I; DeAngelo DJ; Stone RM; Zhang Y; Perkins AS; Shannon K; Hemann MT; Puissant A; Stegmaier K Nat Med; 2017 Mar; 23(3):301-313. PubMed ID: 28191887 [TBL] [Abstract][Full Text] [Related]
19. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. Vasyutina E; Boucas JM; Bloehdorn J; Aszyk C; Crispatzu G; Stiefelhagen M; Breuer A; Mayer P; Lengerke C; Döhner H; Beutner D; Rosenwald A; Stilgenbauer S; Hallek M; Benner A; Herling M Leukemia; 2015 Oct; 29(10):2003-14. PubMed ID: 25936528 [TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]